

1	2	3
2	TB Cell at HQ	2300.00
3	Allocation for OPV	39423.00
4	Central Surveilance Unit (IDSP)	1300.00
	NVBDCP (HQ)	
	SUB TOTAL	44777.04
	GRAND TOTAL	1763853.71

*Note :* The allocation excludes components to under Blindness.

#### **Treatment standard at hospitals for CGHS beneficiaries**

3792. SHRIMATI AMBIKA SONI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether the re-imbursement of costs of treatment and medicines to private hospitals for CGHS covered patients adequately covers good quality care; and

(b) whether there have been any representations by smaller hospitals against slashing of rates of material used in treatment and consequently patients being refused treatment because of this?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABI AZAD): (a) Yes.

(b) There are representations for reconsideration of rates for Angioplasty, which were revised *w.e.f.* 7.2.2013. However, three empanelled hospitals in Delhi filed Writ Petitions in High Court of Delhi against the revision of the rates for Angioplasty and the matter is *sub-judice*.

#### **New guidelines issued by FSSAI**

3793. SHRI KIRANMAY NANDA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether the Food Safety and Standards Authority of India (FSSAI) has recently issued new guidelines to all the food manufacturing companies of India, relating to sale of new or enlisting proprietary food products;

(b) if so, the details thereof and the reasons therefor;

(c) whether Government has consulted the food industry before issuing such guidelines; and

(d) if so, the reaction of the food industry and other stake-holders in this regard?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABI AZAD): (a) to (d) Yes, Food Safety and Standards Authority of India (FSSAI) has issued a new advisory on 11th December, 2012 relating to sale of new or existing proprietary food products. As per Section-22 of the Food Safety and Standards Act, 2006 (FSSA), "no person shall manufacture, distribute, sell or import any novel food, genetically modified articles of food, irradiated food, organic food, foods for special dietary uses, functional foods, nutraceuticals, health supplements, proprietary foods and such other articles of food which the Central Government may notify in this behalf. As on date, there is no standard for these food items in India. Hence, new advisory has been issued in this regard. This advisory has been drafted after detailed consultations.

#### **Introduction of new TB drug**

3794. SHRI A. ELAVARASAN: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether TB is rated as a major public health problem in India and the country accounts for one-fifth of global TB cases;

(b) if so, the details thereof;

(c) whether Government is set to introduce a new TB drug, Bedaquiline, on an experimental basis;

(d) if so, the details thereof;

(e) whether the new drug, Bedaquiline, can kill the TB bacteria quicker than the existing drugs and Indian Medical Council has prepared to introduce the drug under controlled conditions at 4-5 DOTS Plus sites to assess its impact on MDR and XDR-TB; and

(f) if so, the details thereof?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABI AZAD): (a) and (b) Yes. The prevalence of TB cases in the country is showing a declining trend. The estimated prevalence of TB has been brought down from 586/ lakh population (1990) to 249/ lakh population in 2009 as per the WHO global report 2010.